Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue +4.2%, led by Growth Drivers, with growth in every region · Underlying Revenue was solid at +4.2%, with continued strong momentum from Takeda's Growth Drivers (Gastroenterology, Oncology, Neuroscience and Emerging Markets), which grew +9.8%. Key growth products Entyvio (+33.1%) and Ninlaro (+38.0%) were important contributors to revenue, as were the products acquired from Ariad in 2017. Every region achieved positive ...